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ABSTRACT 33 
Bone cells constitutively release ATP into the extracellular environment where it acts locally via 34 
P2 receptors to regulate bone cell function. Whilst P2Y2 receptor stimulation regulates bone 35 
mineralisation the functional effects of this receptor in osteoclasts remain unknown. This 36 
investigation used the P2Y2 receptor knockout (P2Y2R
-/-) mouse model to investigate the role of 37 
this receptor in bone.  MicroCT analysis of P2Y2R
-/- mice demonstrated age-related increases in 38 
trabecular bone volume (≤48%), number (≤30%) and thickness (≤17%). In vitro P2Y2R
-/- 39 
osteoblasts displayed a 3-fold increase in bone formation and alkaline phosphatase activity 40 
whilst P2Y2R
-/- osteoclasts exhibited a 65% reduction in resorptive activity.  Serum cross-linked 41 
c-telopeptide levels (CTX, resorption marker) were also decreased (≤35%). The resorption 42 
defect in P2Y2R
-/- osteoclasts was rescued by the addition of exogenous ATP, suggesting that 43 
an ATP deficit could be a key factor in the reduced function of these cells. In agreement, we 44 
found that basal ATP release was reduced up to 53% in P2Y2R
-/- osteoclasts. The P2Y2 45 
receptor agonists, UTP and 2-thioUTP, ncreased osteoclast activity and ATP release in 46 
wildtype but not P2Y2R
-/- cells.  This indicates that the P2Y2 receptor may regulate osteoclast 47 
function indirectly by promoting ATP release.  UTP and 2-thioUTP also stimulate ATP release 48 
from osteoblasts suggesting that the P2Y2 receptor exerts a similar function in these cells. 49 
Taken together, our findings are consistent with the notion that the primary action of P2Y2 50 
receptor signalling in bone is to regulate extracellular ATP levels.   51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
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INTRODUCTION 60 
Adenosine triphosphate (ATP) has long been recognized for its role in intracellular energy 61 
metabolism; however, it is also exported to the extracellular environment where it acts as an 62 
important signalling molecule (Burnstock 2007a).  Outside cells, ATP and related compounds 63 
act via purinergic receptors to modulate a range of biological processes.  These receptors are 64 
classified into two groups; P1 and P2 receptors. There are four P1 receptors (A1,A2a,A2b,A3), 65 
which are activated by adenosine. The P2 receptors are further subdivided into the P2X ligand-66 
gated ion channels and the P2Y G-protein-coupled receptors.  P2X receptors are activated by 67 
ATP whilst P2Y receptors respond to nucleotides including ATP, adenosine diphosphate 68 
(ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP) (Abbracchio and Burnstock 69 
1994; Burnstock 2007b). Currently, seven P2X receptors (P2X1-7) and eight P2Y receptors 70 
(P2Y1,2,4,6,11-14) have been identified (Burnstock 2007b).    71 
 The P2Y receptors display distinct pharmacology with some being activated by adenine-72 
containing nucleotides (P2Y1, P2Y12, P2Y13), whilst others are stimulated by uridine-containing 73 
nucleotides (P2Y2, P2Y4, P2Y6, P2Y14) (Burnstock 2007a, b).  The primary agonist at the P2Y2 74 
receptor is UTP but it is also activated by ATP. Selective synthetic agonists (e.g. 2-thioUTP) 75 
are also available. Receptor stimulation activates phospholipase C and results in Ca2+ release 76 
from internal stores. Expression of the P2Y2 receptor has been reported in many tissues 77 
including heart, blood vessels, lung, kidney and skeletal muscle (Burnstock 2007a). 78 
Bone cells express multiple P2 receptor subtypes and knowledge of the functional effects of 79 
extracellular nucleotides in bone has increased significantly in recent years (Burnstock, et al. 80 
2013; Gartland, et al. 2012; Noronha-Matos and Correia-de-Sa 2016; Orriss 2015).  P2Y2 81 
receptor expression by osteoclasts has been widely reported (Bowler, et al. 1995; Buckley, et 82 
al. 2002; Hoebertz, et al. 2000; Orriss, et al. 2011b).  Early work using cells from a human 83 
osteoclastoma suggested that ATP could act via the P2Y2 receptor to promote bone resorption 84 
(Bowler et al. 1995).  However, in a follow up study UTP failed to stimulate resorption, 85 
suggesting this was not the case (Bowler, et al. 1998).  To date, there are no studies directly 86 
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describing the functional effects of P2Y2 receptor activation on osteoclasts. In contrast, 87 
activation of several other P2Y receptor subtypes (P2Y1, P2Y6, P2Y12, P2Y14) has been 88 
associated with increased osteoclast formation and/or activity (Hoebertz, et al. 2001; Lee, et al. 89 
2013; Orriss et al. 2011b; Su, et al. 2012; Syberg, et al. 2012b). 90 
The role of the P2Y2 receptor in osteoblasts has been more extensively investigated.  P2Y2 91 
receptor expression by osteoblasts has been extensively reported (Bowler et al. 1995; 92 
Hoebertz et al. 2000; Maier, et al. 1997), with several studies describing that expression is 93 
differentiation-dependent with the highest levels seen in mature, bone forming cells (Noronha-94 
Matos, et al. 2012; Orriss, et al. 2006).  P2Y2 receptor activation in osteoblast-like cells 95 
activates several intracellular signalling pathways including protein kinase C, p38 mitogen-96 
activated protein kinase, c-Jun NH2-terminal protein kinase and RhoA GTPase  (Costessi, et al. 97 
2005; Gardinier, et al. 2014; Katz, et al. 2006, 2008; Pines, et al. 2005).  The P2Y2 receptor has 98 
also been shown to mediate the Ca2+ mobilisation induced by oscillatory fluid flow (You, et al. 99 
2002).  100 
One of the first functional effects to be attributed to the P2Y2 receptor was the inhibition of 101 
bone mineralisation by ATP and UTP (Hoebertz, et al. 2002; Orriss, et al. 2013; Orriss, et al. 102 
2007).  Consistent with this, initial skeletal analysis of 8-week old P2Y2 receptor knockout mice 103 
(P2Y2R
-/-) demonstrated large increases in trabecular and cortical bone parameters in the long 104 
bones (Orriss et al. 2007; Orriss, et al. 2011a).  Furthermore, P2Y2 overexpression leads to 105 
decreased bone formation (Syberg, et al. 2012a) and polymorphisms in the P2Y2 receptor gene 106 
are associated with increased bone mineral density and a decreased risk of osteoporosis 107 
(Wesselius, et al. 2013). In contrast, a recent study using P2Y2R
-/- mice on a different genetic 108 
background, described small decreases in the trabecular bone in knockout animals (Xing, et al. 109 
2014), this work additionally reported that the P2Y2 receptor promotes bone mineralisation.   110 
 The P2Y2 receptor may also have a functional role in mediating osteoblast 111 
mechanosensitivity. Studies suggest that the P2Y2 receptor promotes mechanotransduction 112 
(Xing et al. 2014) and  increases cell stiffness and cytoskeletal rearrangement in response to 113 
fluid shear stress (Gardinier et al. 2014). 114 
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Expression of the P2Y2 receptor has also been reported in MLO-Y4 osteocyte-like cells 115 
(Kringelbach, et al. 2014).  The same study also demonstrated controlled ATP release from 116 
these cells and reported that UTP, probably acting via the P2Y2 or P2Y4 receptors, increased 117 
this ATP release. 118 
 Available evidence thus indicates that the P2Y2 receptor plays significant, although not yet 119 
fully defined roles in regulating bone remodelling.  This study used the P2Y2R
-/- mouse, which 120 
was first generated almost 2 decades ago (Cressman, et al. 1999),  to determine how P2Y2 121 
receptor-mediated signalling influences bone cell function in vitro and in vivo, with a particular 122 
focus on its effects in osteoclasts.  123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
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METHODS 141 
Reagents 142 
Tissue culture reagents were purchased from Life Technologies (Paisley, UK); unless 143 
mentioned, all chemicals were purchased from Sigma Aldrich (Poole, Dorset, UK).  UTP and 2-144 
thioUTP were purchased from Tocris Bioscience (Bristol, UK).   145 
Animals 146 
Mice lacking the P2Y2 receptor gene (P2Y2R
-/-) were obtained from Jackson Laboratories (Bar 147 
Harbor, Maine, USA).  The generation and characterisation of P2Y2R
-/- mice (C57BL/6J 148 
background) has been previously described (Homolya, et al. 1999).  All animals were housed 149 
under standard conditions with free access to food and water. Animals were bred from 150 
homozygote (P2Y2R
-/-) and parental strain wildtype (P2Y2R
+/+) breeding pairs. All procedures 151 
complied with the UK animals (Scientific Procedures) Act 1986 and were reviewed and 152 
approved by the Royal Veterinary College Research Ethics Committee.  153 
Microcomputed x-ray tomographic (µCT) analysis of P2Y2R
-/- mice 154 
The tibiae and femora were isolated from male 4, 8, 16 and 24-week old P2Y2R
-/- and P2Y2R
+/+ 155 
mice (n=10), fixed in 10% neutral buffered formalin (NBF) for 24 hours and stored in 70% 156 
ethanol until scanning.  µCT analysis of trabecular and cortical bone parameters was 157 
performed on the tibial and femoral metaphysis (SkyScan 1172, Bruker, Belgium). The 158 
appearance of the first cartilage bridge was used as a reference point, with an offset of 0.4mm 159 
and 2.5mm for trabecular and cortical bone, respectively. In all cases the length of bone 160 
analysed was 1mm.  The µCT scanner was set at 50Kv and 200µA using a 0.5mm Al filter and 161 
a resolution of 4.3µm.  Analysis of isolated bones was performed blind.  The images were 162 
reconstructed, analysed and visualised using SkyScan NRecon, CTAn and CTVol software. 163 
Bone mineral density (BMD) was calibrated and calculated using hydroxyapatite phantoms with 164 
a known density.  165 
 166 
Page 6 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
7 
 
Osteoblast formation assay 167 
Osteoblasts were isolated from the calvariae of 3-5 day old P2Y2R
+/+ or P2Y2R
-/- mice by 168 
trypsin/collagenase digestion as previously described (Orriss, et al. 2012b; Taylor, et al. 2014). 169 
Cells were cultured for up to 21 days in alpha Minimum Essential Medium, (αMEM) 170 
supplemented with 2mM β-glycerophosphate and 50µg/ml ascorbic acid, with half medium 171 
changes every 3 days. The total area of bone nodules formed was quantified by image 172 
analysis, as described previously (Orriss et al. 2012b).  173 
Primary osteoblasts of bone marrow/stromal cell origin were obtained from the long bones of 174 
6-week old male P2Y2R
+/+ or P2Y2R
-/- animals. The collected cells were suspended in α-MEM 175 
and pre-cultured in a 75 cm2 flask in 5% CO2 at 37ºC. After 24 hours the α-MEM was replaced 176 
in order to eliminate non-adherent cells; adherent stromal cells were cultured for a further 7 177 
days. When confluent, cells were plated into 6-well trays and cultured as above.   178 
Alkaline phosphatase (TNAP) activity 179 
Osteoblast TNAP activity was measured in cell lysates taken at defined stages of osteoblast 180 
differentiation as previously described (Orriss et al. 2012b; Taylor et al. 2014).  TNAP activity 181 
was normalised to cell protein using Bradford reagent. Time points in osteoblast cultures were 182 
defined thus:  proliferating (day 4, calvarial only); differentiating (day 7); mature (day 14) and 183 
mature, bone-forming (day 21) 184 
Osteoclast formation assay 185 
Osteoclasts were isolated from the long bones of 6-8 week-old male P2Y2R
+/+ or P2Y2R
-/-mice 186 
as described previously (Orriss and Arnett 2012).  Cells were plated onto 5mm diameter ivory 187 
discs (106 cells) in 96-multiwells in αMEM supplemented with 10% FCS, 5% gentamicin, 100nM 188 
PGE2, 200ng/ml M-CSF and 3ng/ml receptor activator of nuclear factor ΚB ligand (RANKL, R&D 189 
Systems Europe Ltd, Abingdon, UK).  After 24 hours, discs containing adherent osteoclast 190 
precursors were transferred to 6-well trays (4 discs/well in 4ml medium) for a further 6 days.  191 
Culture medium was acidified to pH~7.0 by the addition 10meq/l H+ (as HCL) on day 7 to 192 
activate resorption (Orriss and Arnett 2012).  P2Y2 receptor agonists (10nM-10µM UTP or 2-193 
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thioUTP) were added from day 3 of culture.  Apyrase (a broad spectrum ecto-nucleotidase) was 194 
used to determine the effects of endogenous ATP.  195 
Osteoclasts were fixed in 2.5% glutaraldehyde and stained to demonstrate tartrate-resistant 196 
acid phosphatase (TRAP). Osteoclasts were defined as TRAP-positive cells with 2 or more 197 
nuclei and/or clear evidence of resorption. The total number of osteoclasts and the plan surface 198 
area of resorption pits on each disc was assessed ‘blind’ by transmitted light microscopy  and 199 
reflective light microscopy and dot-counting morphometry, respectively. 200 
Measurement of serum bone markers 201 
Blood was collected from 4, 8, 16 and 24-week old male P2Y2R
-/- and P2Y2R
+/+ mice by cardiac 202 
puncture immediately after termination.  Following clotting, samples were centrifuged at 500g 203 
and the serum frozen until analysis.  Levels of the bone formation marker, N-terminal propeptide 204 
of type I collagen (P1NP) and the bone resorption marker, cross-linked C-telopeptide (CTX) 205 
were assayed using the P1NP and RatLaps™ ELISAs, respectively (Immunodiagnostics 206 
Systems Ltd, UK).  207 
Histology 208 
Histological analysis was performed on the femur of 8 and 24-week old male P2Y2R
+/+ or 209 
P2Y2R
-/-mice. Tissues were fixed in 10% NBF, decalcified in 10% EDTA for three weeks and 210 
embedded in paraffin wax blocks.  Serial sections were cut every 5µm and slides stained with 211 
TRAP counterstained with haematoxylin to visualise osteoclasts.  212 
Total RNA extraction and DNase treatment 213 
P2Y2R
+/+ and P2Y2R
-/- osteoclasts were cultured on dentine discs for 9 days (mature, resorbing 214 
cells) before total RNA was extracted using TRIZOL reagent (Invitrogen, Paisley, UK) 215 
according to the manufacturer’s instructions.  Osteoblasts were cultured for 14 days (mature, 216 
bone-forming cells) before RNA collection.  Extracted RNA was treated with RNase-free DNase 217 
I (35U/ml) for 30 min at 37°C. The reaction was terminated by heat inactivation at 65°C for 10 218 
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min.  Total RNA was quantified spectrophotometrically by measuring absorbance at 260nM.   219 
RNA was stored at –80°C until amplification by qRT-PCR. 220 
Quantitative real time polymerase chain reaction (qRT-PCR) 221 
Osteoclast and osteoblast RNA (50ng) was transcribed and amplified using the qPCRBIO 222 
SyGreen one-step qRT-PCR kit (PCR Biosystems, London, UK), which allows cDNA synthesis 223 
and PCR amplification to be carried out sequentially.  qRT-PCR was performed according to 224 
manufacturer’s instructions with initial cDNA synthesis (45°C for 10 min) and reverse 225 
transcriptase inactivation (95°C for 2 min) followed by 40 cycles of denaturation (95°C for 5 226 
sec) and detection (60°C for 30 sec). All reactions were carried out in triplicate using RNAs 227 
derived from 4 different cultures.  Data were analysed using the Pfaffl method of relative 228 
quantification (Pfaffl 2001). Primers were obtained from Qiagen Ltd (Manchester, UK).  229 
Measurement of ATP release  230 
Prior to measurement of ATP release, culture medium was removed, cell layers washed and 231 
cells incubated with serum-free DMEM (phenol red free).  To measure the effects of P2Y2 232 
receptor deletion on basal ATP release, samples were collected after 1 hour and immediately 233 
measured luminometrically using the luciferin-luciferase assay, as described previously  234 
(Orriss, et al. 2009).  All ATP measurements were normalised to cell number.  Cell viability and 235 
cell number were determined using the CytoTox 96® colorimetric cytotoxicity assay (Promega 236 
UK, Southampton UK). 237 
To examine the effects of acute exposure to UTP or 2-thioUTP (0.1-50µM) agonists were 238 
added to the serum-free DMEM and samples taken for quantification after 10, 30, 60 and 90 239 
minutes.  The luminescence of the DMEM (± UTP/2-thioUTP) was used as a background 240 
reading and subtracted from the relevant measurements. Standard curves used to calculate the 241 
ATP concentrations in the presence or absence of UTP/2-thioUTP are shown in Fig. 5.  To 242 
investigate the effects of long-term treatment with P2Y2 receptor agonists, osteoclasts and 243 
osteoblasts were cultured with UTP or 2-thioUTP (0.1-100µM) for 7 or 14 days, respectively. 244 
Fresh UTP/2-thioUTP was added at each medium exchange.  On the day of assay culture 245 
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medium was removed and cells incubated with serum-free DMEM without agonists.  Samples 246 
were collected after 1 hour and measured immediately.  247 
To determine the effects of P2Y2 deletion on ATP breakdown, cells were swapped to DMEM 248 
containing 1µM ATP and samples taken after 2, 5, 10, 30 and 60 minutes.  249 
Statistical analysis 250 
Data were analysed using GraphPad Prism 6 software (San Diego, CA).  Results are 251 
expressed as means ± SEM for between 6-12 biological replicates.  Statistical analyses of bone 252 
parameters were performed by two-tailed unpaired student’s t-test.  In vitro data were analysed 253 
using an unpaired student’s t-test, one-way or two-way ANOVA, followed by a Bonferroni post 254 
hoc test.  For all in vitro work, results are representative of experiments performed at least 255 
three times, using cells isolated from different animals.   256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
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RESULTS 273 
P2Y2R
-/-mice show age-related increases in trabecular bone 274 
High resolution µCT analysis revealed that P2Y2R
-/- mice display increased levels of trabecular 275 
bone compared to age-matched P2Y2R
+/+ controls. These differences appear to be age-related 276 
with the biggest changes observed in the 24-week animals.  Trabecular bone volume (BV/TV) 277 
was increased ≤46% in the femur and ≤48% in the tibia of P2Y2R
-/- mice (Fig. 1A-1B, 1O).  278 
Trabecular number (Tb.N) was increased ≤27% in the femora (Fig. 1C, 1O) and ≤30% in the 279 
tibiae (Fig. 1D, 1O).  Trabecular thickness (Tb.Th) was unchanged up to 8 weeks of age but 280 
increased ≤10% and ≤17% at 16 and 24 weeks, respectively (Fig. 1E-1F, 1O).  Trabecular 281 
bone mineral density (Tb.BMD) was ≤12% higher in P2Y2R
-/- mice (Fig. 1G-1H). No differences 282 
were observed in the cortical bone volume (Fig. 1K-1L, 1O), cortical thickness (Fig. 1K-1L), 283 
endosteal and periosteal diameter (Fig. 1M-1N) and bone length at any age. 284 
Increased bone formation by osteoblasts from P2Y2R
-/- mice 285 
The level of mineralised bone nodule formation was increased ~3-fold in P2Y2R
-/- calvarial 286 
osteoblasts (Fig. 2A, 2G) and 5-fold in P2Y2R
-/- long bone osteoblasts (Fig. 2B).  P2Y2 receptor 287 
deletion increased basal TNAP activity (≤3-fold) in calvarial and long bone osteoblasts at all 288 
stages of differentiation with the largest effects being observed in the mineralising cells (Fig. 289 
2C-2D).  Serum TNAP activity was up to 60% higher in P2Y2R
-/- animals (Fig. 2E); no 290 
differences were observed in the serum P1NP levels (Fig. 2F).  No differences in total protein 291 
content were observed in any TNAP activity experiments. 292 
Osteoclasts from P2Y2R
-/- mice exhibit defective resorption 293 
Whilst no differences in osteoclast numbers were observed (Fig. 3A, 3D), the level of 294 
resorption per osteoclast was decreased 75% in P2Y2R
-/- cultures (Fig. 3B, 3D).  Serum CTX 295 
levels were reduced up to 35% in P2Y2R
-/- mice (Fig. 3C).  Qualitative histology suggested that 296 
decreased numbers of osteoclasts were evident on the trabecular and endocortical bone 297 
surfaces of 24-week old P2Y2R
-/-; however, no differences were observed in 8-week old 298 
animals (Fig. 3E). 299 
Page 11 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
12 
 
Changes in gene expression in P2Y2R
-/- osteoclasts and osteoblasts 300 
The effect of P2Y2 receptor deletion on the expression of resorption associated genes and 301 
ecto-nucleotidases was investigated in mature, resorbing osteoclasts.  mRNA expression of 302 
many genes (TRAP, CICN7, RANK, c-fms) showed a downward trend but only cathepsin K 303 
expression was significantly reduced (4.8-fold). Osteoclasts express a range of ecto-304 
nucleotidases that hydrolyse ATP (Hajjawi, et al. 2014) and NDPK (nucleoside 305 
disphosphokinase), which can regenerate ATP from ADP.  P2Y2 receptor deletion did not 306 
influence the expression of any of these genes (Table 1).  307 
In osteoblasts, deletion of the P2Y2 receptor increased osteocalcin (Ocn), osteopontin (Opn) 308 
and osteoprotegerin (OPG) expression 3.3, 6 and 4.5-fold, respectively.  The mRNA expression 309 
of Col1α1, Runx2, TNAP, osteonectin, RANKL, MCSF and the ecto-nucelotidases was 310 
unchanged (Table 1).  311 
Activation of the P2Y2 receptor increases bone resorption 312 
Treatment with UTP and 2-thioUTP had no effect on osteoclast formation in P2Y2R
+/+ or P2Y2R
-
313 
/- cells (Fig. 4A-4B). However, the area resorbed per osteoclast was dose-dependently 314 
increased by up to 80% and 45% in P2Y2R
+/+ cells treated with UTP and 2-thioUTP (≥100nM), 315 
respectively. No effects on resorption were seen in P2Y2R
-/- osteoclasts (Fig. 4C-4D).    316 
Reversal of resorption defect in P2Y2R
-/- osteoclasts by extracellular ATP 317 
P2Y2R
-/- osteoclasts displayed a 53% reduction in ATP release (Fig. 4E) but showed no 318 
difference in the rate of ATP breakdown (Fig. 4F).  Apyrase (≥1U/ml), a broad spectrum ecto-319 
nucleotidase that rapidly degrades ATP and ADP, inhibited bone resorption by up to 55% (Fig. 320 
4G). To determine if reduced extracellular ATP was the cause of the decreased resorption seen 321 
in P2Y2R
-/- osteoclasts, cells were cultured with exogenous ATP (1-10µM).  Treatment with ATP 322 
(≥1µM) fully rescued the resorption defect see in P2Y2R
-/- osteoclasts (Fig. 4H). 323 
P2Y2 receptor agonists increase ATP release from osteoclasts 324 
In P2Y2R
+/+ cells, 10 minutes after addition of UTP (≥1µM) extracellular ATP levels were 325 
doubled; the increase in ATP levels was sustained for up to 90 minutes post treatment (Fig. 326 
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5A). No effect of UTP on ATP release was seen in P2Y2R
-/- osteoclasts at any stage (Fig. 5B-327 
5D). Treatment with 2-thioUTP (≥0.1µM) also dose dependently increased extracellular ATP 328 
levels by ≤50% for up to 90 minutes in P2Y2R
+/+  osteoclasts (Fig. 5E); 2-thioUTP was without 329 
effect in P2Y2R
-/- cells (Fig. 5F-5H).   330 
The effect of long-term treatment (7 days) with P2Y2 receptor agonists on basal ATP release 331 
was also investigated in mature osteoclasts.  In P2Y2R
+/+ cells, UTP and 2-thioUTP (≥1µM) 332 
increased ATP release by up to 70% and 65% respectively (Fig.5I-5J).  No increase in ATP 333 
release was seen in P2Y2R
-/- osteoclasts. Standard curves used to calculate ATP levels are 334 
shown in Fig. 5K-5L.  In all experiments, cell viability was unchanged (not shown). 335 
ATP release from osteoblasts is stimulated by UTP and 2-thioUTP 336 
The rate of ATP breakdown was unchanged in P2Y2R
-/- osteoblasts (Fig. 6A). ATP release 337 
from P2Y2R
-/- cells was decreased (≤60%) at all stages of differentiation (Fig. 6B). Long-term 338 
treatment (14 days) with UTP and 2-thioUTP increased the levels of ATP release by up to 4-339 
fold and 3-fold, respectively, in P2Y2R
+/+ost oblasts (Fig. 6C-6D).  No effects were seen in 340 
P2Y2R
-/- osteoblasts.   341 
Acute UTP treatment increased ATP release from P2Y2R
+/+ osteoblasts up to 4-fold within 342 
10 minutes; stimulatory effects were sustained for up to 60 minutes (Fig. 6E).  UTP was without 343 
effect in P2Y2R
-/- osteoblasts (Fig. 6F-6H).  2-thioUTP also enhanced ATP release (≤4-fold) 344 
from P2Y2R
+/+, but not P2Y2R
-/- osteoblasts (Fig. 6I-6L).  345 
 346 
 347 
 348 
 349 
 350 
 351 
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DISCUSSION  352 
This study examined the role of P2Y2 receptor-mediated signalling in osteoclasts and 353 
osteoblasts.  We found that global deletion of the P2Y2 receptor resulted in greater amounts of 354 
trabecular bone and increased BMD.  Culture of cells derived from P2Y2R
-/- mice revealed that 355 
osteoclast resorptive activity was decreased whilst bone mineralisation was increased. 356 
Mechanistic analysis revealed that P2Y2 receptor activation (acute and prolonged) promotes 357 
ATP release from osteoclasts and osteoblasts.   358 
Several P2Y receptors (P2Y1, P2Y6, P2Y12, P2Y14) and extracellular nucleotides (e.g. ATP, 359 
ADP, UDP) have been implicated in the regulation of osteoclast formation and activity 360 
(Hoebertz et al. 2001; Lee et al. 2013; Orriss et al. 2011b; Su et al. 2012; Syberg et al. 2012b).  361 
However, there are no reports directly describing the functional role of the P2Y2 receptor in 362 
osteoclasts. This study found that the P2Y2 agonists, UTP and 2-thioUTP, dose-dependently 363 
stimulated bone resorption. Consistent with a pro-resorptive role for UTP and the P2Y2 364 
receptor, we observed that P2Y2R
-/- animals had decreased serum CTX levels and that cultured 365 
P2Y2R
-/- osteoclasts displayed reduced resorptive activity and cathepsin K expression. UDP, 366 
the breakdown product of UTP, acts via the P2Y6 receptor to promote osteoclast function 367 
(Orriss et al. 2011b). However, since the actions of UTP are lost in P2Y2R
-/- osteoclasts, it is 368 
unlikely that the effects observed here are due to P2Y6 receptor-mediated signalling.  369 
Earlier studies have reported that P2Y2 receptor activation by ATP and UTP can both inhibit 370 
(Hoebertz et al. 2002; Orriss et al. 2007; Orriss, et al. 2012a) and promote (Xing et al. 2014) 371 
bone mineralisation. Consistent with its role as a negative regulator of bone mineralisation, we 372 
observed that P2Y2R
-/- osteoblasts exhibited increased levels of bone formation, Ocn 373 
expression and TNAP activity. Suprisingly, TNAP mRNA expression was unaffected in P2Y2R
-/- 374 
osteoblasts. This could indicate that P2Y2 receptor signalling increases enzyme activity by 375 
influencing the post-translational modifications of TNAP rather than the overall expression level. 376 
We have previously shown that the effects of ATP and UTP are restricted to the mineralisation 377 
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process with collagen expression and activity being unaffected (Orriss et al., 2007).  The lack of 378 
effect of P2Y2 receptor deletion on serum P1NP levels is consistent with these observations. 379 
In agreement with the in vitro findings, our longitudinal µCT study revealed that P2Y2 380 
deletion led to age-related increases in trabecular bone and BMD. These data are also 381 
consistent with our earlier description of the bone phenotype of 8-week old P2Y2R
-/- animals 382 
(Orriss et al. 2011a), and the observation that P2Y2 receptor overexpression leads to 383 
decreased bone formation (Syberg et al. 2012a).  However, they are at variance to a recent 384 
report of reduced bone levels in P2Y2R
-/- mice (Xing et al. 2014).  The reasons for these 385 
divergent results are unclear but given that parental strain has been shown to affect the 386 
phenotype of the P2X7 receptor knockout (Syberg, et al. 2012a), the differing genetic 387 
background of the animals studied (C57BL/6 compared to SV129 (Xing et al. 2014)) could be a 388 
factor. Variations in µCT methodology could also contribute; for example, this study analysed a 389 
1mm region of the trabecular bone within the metaphyseal portion of the long bones at a 390 
resolution of 4.3µm.  In contrast, Xing et al measured the trabecular bone within a narrow 391 
region of the diaphysis at a lower resolution (10.5µm) (Xing et al. 2014). 392 
Unlike the observed effects in the trabecular bone, in both this study and that of Xing et al 393 
(Xing et al. 2014), cortical bone parameters were unaffected in P2Y2R
-/- mice.  This suggests 394 
that P2Y2 receptor deletion does not have significant effects on bone growth. Thus,  P2Y2 395 
receptor-mediated signalling appears to be more important in bone undergoing rapid turnover.   396 
In vivo, osteoblast and ostoclast function are tightly coupled with osteoclast activation being 397 
dependent on osteoblasts.  Gene expression analysis revealed a significant increase in 398 
osteoblast expression of OPG whilst RANKL expression was unchanged.  If reflected in vivo 399 
this would reduce osteoclast formation and activity and could contribute to the decreased bone 400 
resorption seen in P2Y2R
-/- mice.  In agreement, qualitative observations showed that 401 
osteoclast numbers on the trabecular and endocortical bone surfaces appeared reduced in 402 
these animals. Further bone histomorphometric analysis of in vivo parameters such as bone 403 
formation rate and osteoclast number would confirm this and build on the findings reported 404 
here.   405 
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 Controlled ATP release has been demonstrated from numerous cell types including bone 406 
cells.  Several studies have indicated that the primary method of ATP release from osteoblasts 407 
is vesicular exocytosis (Genetos, et al. 2005; Orriss et al. 2009; Romanello, et al. 2001), 408 
although the P2X7 receptor may also be involved (Brandao-Burch, et al. 2012).  In osteoclasts, 409 
ATP release involves the P2X7 receptor (Brandao-Burch et al. 2012; Pellegatti, et al. 2011).  410 
Increasing evidence now suggests that ATP can act to enhance its own release; ATP or UTP-411 
induced ATP release has been demonstrated from MLO-Y4 osteocyte-like cells (Kringelbach et 412 
al. 2014), leukocytes (De Ita, et al. 2016), urothelial cells (Mansfield and Hughes 2014) and 413 
cells from the carotid body (Zhang, et al. 2012).  The P2Y2 receptor is thought to mediate this 414 
increased ATP release in cells including osteocytes (Kringelbach et al. 2014) and leukocytes 415 
(De Ita et al. 2016).  Therefore we investigated whether UTP could exert its functional effects 416 
on bone cells indirectly i.e. acting via the P2Y2 receptor to induce ATP release. We found that 417 
P2Y2R
-/- osteoblasts and osteoclasts showed reduced levels of basal ATP release. 418 
Furthermore, UTP and 2-thioUTP increased ATP release from these cells following both acute 419 
(≤90 minutes) and long-term (≤14 days) treatment. These stimulatory effects were lost in 420 
P2Y2R
-/- cells suggesting that the increased extracellular ATP levels were mediated via P2Y2 421 
receptor signalling. For the long-term experiments, UTP and 2-thioUTP were present in the 422 
culture medium for the 7 or 14 days days prior to testing but not in the medium used for the 423 
subsequent ATP release assay. This suggests that repeated P2Y2 receptor stimulation could 424 
induce changes to the cellular processes which regulate ATP efflux from bone cells.  However, 425 
at present, the mechanisms by which this could occur are unknown.  Interestingly,  P2Y2 426 
receptor activation in osteoblast-like cells has been shown to induce to actin fibre formation in 427 
response to fluid shear stress (Gardinier et al. 2014).  This ability to regulate cytoskeletal 428 
rearrangement could result in alterations in the vesicular release pathway. 429 
 Extracellularly, ATP is rapidly broken down by ecto-nucleotidases, restricting its actions to 430 
cells close to the release site (Zimmermann, et al. 2012).  The rate of ATP breakdown and the 431 
mRNA expression of ecto-nucleotidases (NPPs, NTPdases) were unchanged in P2Y2R
-/- cells.  432 
Thus, our findings suggest that the primary effect of P2Y2 receptor activiation is to stimulate the 433 
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level of ATP release from bone cells rather than influence the rate of ATP degradation or 434 
regeneration.   435 
 Following release, ATP can act on other P2 receptors to influence the function of 436 
surrounding cells. In osteoclasts, ATP and its breakdown product ADP act via the P2Y1 and/or 437 
P2Y12 receptors to promote bone resorption (Hoebertz et al. 2001; Su et al. 2012).  Thus, our 438 
finding that P2Y2 receptor activation promotes ATP release suggest indrect actions of UTP on 439 
bone resorption (a potential mechanism of action is shown in Fig. 7).  Consistent with this idea, 440 
we observed that addition of exogenous ATP rescued the resorption defect in P2Y2R
-/- 441 
osteoclasts; although not studied here ADP would be expected to have a similar effect.  442 
Furthermore, apyrase, which breaksdown all endogenous ATP, inhibited osteoclast activity. 443 
The use of apyrase is likely to cause a rapid accumulation of adenosine. We have shown that 444 
adenosine has no effect on osteoclast function (Hajjawi, et al. 2016) whilst others report it 445 
promotes resorption (Kara, et al. 2010).  If the actions of apyrase were a consequence of 446 
higher adenosine levels, an increase (or no effect) in resorption would be expected.  However, 447 
since we observed the opposite it is more likely that the functional effects of apyrase are due to 448 
reduced extracellular ATP levels.  449 
 The role of purinergic signalling in osteoblasts has been widely studied and for some P2 450 
receptors multiple functional effects have been described (Burnstock et al. 2013; Gartland et al. 451 
2012; Noronha-Matos and Correia-de-Sa 2016; Orriss 2015). The diverse range of 452 
experimental models and culture conditions employed in vitro has often resulted in conflicting or 453 
confounding results regarding these actions.  This is particurly evident for the P2Y2 and P2X7 454 
receptors, stimulation of which has been shown to both inhibit and promote bone mineralisation 455 
(Noronha-Matos, et al. 2014; Orriss et al. 2012a; Orriss et al. 2007; Panupinthu, et al. 2007; 456 
Xing et al. 2014).  The data presented here show that P2Y2 deletion leads to increased levels of 457 
bone mineralisation.  Based on our findings one potential mechanism of action is summarised 458 
in Fig. 7.  We  suggest that UTP acts at the P2Y2 receptor to stimulate ATP release, once 459 
released ATP can then act via other P2 receptors to block bone mineralisation (Orriss et al. 460 
Page 17 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
18 
 
2012a), as well as exerting a direct physiochemical blockade via its breakdown product, 461 
pyrophosphate (Orriss et al. 2007; Orriss, et al. 2016). 462 
Fluid flow and mechanical stress are well known stimulators of osteoblast ATP release 463 
(Genetos et al. 2005; Romanello et al. 2001; Rumney, et al. 2012).  This enhanced release of 464 
ATP has been implicated in mechanically-induced bone formation via increased prostaglandin 465 
E2 (PGE2) secretion (Genetos et al. 2005).  However, the ATP levels required to induce PGE2 466 
production are 10-fold higher than those needed to inhibit mineralisation and may only occur 467 
following mechanical stress. These potentially confounding actions serve to illustrate the highly 468 
complex, local effects of purinergic signalling on bone cell function. Thus, how a bone cell 469 
responds to these signals is likely to be influenced by factors including local nucleotide 470 
concentration, receptor expression profile, ecto-nucleotidase expression and activity, and, for 471 
osteoblasts and osteocytes, degree of mechanical stress experienced. 472 
  In conclusion, this study describes, for the first time, a role for the P2Y2 receptor in 473 
regulating osteoclast function. The in vitro findings also provide further support for the inhibitory 474 
actions of P2Y2 receptor signalling on bone mineralisation under normal conditions. Taken 475 
together our findings indicate that the P2Y2 receptor modulates bone homeostasis by regulating 476 
extracellular ATP levels and, consequently, local purinergic signalling.  477 
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FIGURE LEGENDS 
Figure 1.  P2Y2R
-/- mice display age-related increases in trabecular bone. 
Trabecular bone volume (BV/TV) was increased by ≤46% and ≤48% in the (A) femur and 
(B) tibiae of P2Y2R
-/- mice, respectively.  Trabecular number (Tb.N) was increased (C) ≤27% 
in the femur and (D) ≤30% in the tibia.  Trabecular thickness (Tb.Th) was ≤17% and ≤10% 
higher in the (E) femur and (F) tibia, respectively.  (G, H) Trabecular BMD was increased 
≤12%. (I, J) Cortical bone volume, (K, L) cortical thickness, (M) periosteal diameter and (N) 
endosteal diameter were unchanged. Values are means ± SEM (n=10), significantly different 
from controls: * = p<0.05, ** = p<0.01, *** = p<0.001.  (O) Representative 3D volumetric 
images of the trabecular and cortical bone of 24-week old P2Y2R
-/- and P2Y2R
+/+ mice 
Figure 2.  Increased bone formation by osteoblasts from P2Y2R
-/- mice  
In cultures of (A) calvarial and (B) long-bone osteoblasts from P2Y2R
-/- mice the level of 
mineralised bone nodule formation was increased 3-fold and 5-fold, respectively.  Basal 
TNAP activity was increased by ≤3-fold in P2Y2R
-/-  (C) calvarial and (D) long bone 
osteoblasts (n = 6).  (F) Serum TNAP activity was increased up to 60% (n = 10).  (E) Serum 
P1NP levels were unchanged in P2Y2R
-/- mice (n = 10).  Values are means ± SEM, 
significantly different from controls: * = p<0.05,  ** = p<0.01, *** = p<0.001. (G) 
Representative whole well scans (unstained) and phase contrast microscopy images 
(alizarin red stained) showing the increased bone formation in cultures of P2Y2R
-/- calvarial 
osteoblasts.  Scale bars: whole well = 0.5cm, microscopy images = 50µm.   
Figure 3.  Osteoclasts from P2Y2R
-/- mice exhibit defective resorption 
P2Y2 receptor deletion (A) had no effect on osteoclast number but (B) decreased resorption 
per osteoclast by 75% (n = 8). (C) Serum CTX levels were up to 35% lower in P2Y2R
-/- mice 
(n = 10). Values are means ± SEM, significantly different from controls: * = p<0.05, *** = 
p<0.001.  (D)  Representative transmitted and reflective light microscopy images showing 
the decreased resorption seen in P2Y2R
-/- osteoclast cultures. Scale bar = 50µm. (E) 
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Qualitative histology suggested that the number of TRAP-positive osteoclasts was reduced 
on the endocortical and trabecular bone surfaces in 24-week but not 8-week old P2Y2R
-/- 
mice.   Scale bar = 100µm 
Figure 4.  The role of the P2Y2 receptor and extracellular ATP in regulating bone 
resorption 
Treatment with (A) UTP (B) 2-thioUTP had no effect on osteoclast formation.  The area 
resorbed per osteoclast was increased up to (C) 80% by UTP and (D) 45% by 2-thioUTP 
(≥10nM) in P2Y2R
+/+ but not P2Y2R
-/- osteoclasts, (E) P2Y2R
-/- osteoclasts mice displayed a 
53% reduction in basal ATP release.  (F) ATP breakdown was unchanged in P2Y2R
-/- 
osteoclasts. (G) Culture with apyrase inhibited bone resorption in normal osteoclasts by up 
to 55%.  (H) Addition of exogenous ATP (≥1µM) returned the level of resorption in P2Y2R
-/- 
osteoclast cultures to normal. Valu s are means ± SEM (n = 8), significantly different from 
controls: * = p<0.05, ** = p<0.01,  *** = p<0.001. 
Figure 5.  The effect of UTP and 2-thioUTP on ATP release from osteoclasts 
(A) UTP (≥1µM) increased extracellular ATP release by ≤2-fold for up to 90 minutes post-
treatment. (B,C,D) No effects of UTP on ATP released were seen P2Y2R
-/- cells.  (E) 2-
thioUTP (≥0.1µM) dose-dependently increased extracellular ATP levels by up to 50% (F, G, 
H) but had no effect in P2Y2R
-/- osteoclasts.  Long-term  treatment (7days) with (I) UTP and 
(J) 2-thioUTP treatment enhanced ATP release by up to 70% and 65%, respectively in 
P2Y2R
+/+ but not P2Y2R
-/- osteoclasts. Values are means ± SEM (n = 10), significantly 
different from controls: * = p<0.05, ** = p<0.01,  *** = p<0.001. Differences between P2Y2R
+/+ 
and P2Y2R
-/-: # = p<0.05, ## = p<0.01, ### = p<0.001.  Standard curves used to calculate 
ATP concentrations in acute (K) UTP and (L) 2-thioUTP experiments. 
Figure 6.  The role of the P2Y2 receptor in ATP release from osteoblasts 
(A) No differences were observed in the rate of ATP breakdown between P2Y2R
+/+ and 
P2Y2R
-/- osteoblasts.  (B) Basal ATP release was up to 60% lower from P2Y2R
-/- osteoblast. 
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Increased ATP release from P2Y2R
+/+ but not P2Y2R
-/- osteoblasts treated for 14 days with 
(C) UTP (≤4-fold) and (D) 2-thioUTP (≤3-fold). (E) Acute treatment with UTP (≥10µM) 
increased ATP release by ≤4-fold for up to 60 minutes.  (F,G,H) No effect of UTP (10µM) on  
ATP release from P2Y2R
-/- osteoblasts. (I) ≥1µM 2-thioUTP also enhanced ATP release (≤4-
fold) from P2Y2R
+/+osteoblasts but was without effect in P2Y2R
-/- cells (J,K,L). Values are 
means ± SEM (n = 12), significantly different from controls: * = p<0.05, ** = p<0.01,  *** = 
p<0.001. Differences between P2Y2R
+/+ and P2Y2R
-/-: # = p<0.05, ## = p<0.01, ### = 
p<0.001. 
Figure 7.  Proposed role of the P2Y2 receptor in osteoclast and osteoblast function 
In osteoclasts, UTP acts via the P2Y2 receptor to promote the release of ATP (via the P2X7 
receptor).  Once released ATP (and ADP) can act via the P2Y1 and / or P2Y12 receptors to 
stimulate bone resorption. UTP can also act via the P2Y2 receptor to stimulate ATP release 
from osteoblasts (via vesicular exocytosis).  ATP can then act via other P2 receptors (e.g. 
P2X1 or P2X7) to inhibit bone mineralisation.  ATP can also be broken down by NPP1 to 
produce the mineralisation inhibitor, pyrophosphate (PPi). 
 
Page 27 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
P2Y2R
+/+ P2Y2R
-/- 
O 
Page 28 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review OnlyP2Y2R+/+ P2Y2R-/- G 
Page 29 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
  A B  C 
D 
Transmitted light 
P2Y2R
-/- P2Y2R
+/+ P2Y2R
+/+ P2Y2R
-/- 
Reflected light 
Cultured 
osteoclasts 
Trabecular bone surface Endocortical bone surface 
8-week 
femur 
24-week 
femur 
E 
Page 30 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
Page 31 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
Page 32 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
Page 33 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
UTP / ATP 
P2Y2 receptor 
OSTEOCLAST 
ATP 
P2X7 
receptor 
P2Y1 / P2Y12 
receptor 
Pi + 
ADP 
OSTEOBLASTS 
bone resorption 
ATP 
AMP + 
PPi 
bone 
mineralisation 
NPP1 
NTPD1 
P2X1 / P2X7 
receptor 
ATP breakdown 
Acting on receptors 
ATP release 
Functional effects 
BONE MATRIX 
OSTEOCLAST 
Page 34 of 36
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
1 
 
Table 1: The effect of P2Y2 receptor deletion on gene expression in osteoblasts and 
osteoclasts 
Gene 
Fold change in 
expression 
Gene 
Fold change in 
expression 
Osteoclasts    
RANK -2.6 ± 0.66 NPP1 -2.83 ± 0.47 
Cathepsin K -4.8 ± 0.13*  NPP3 1.14 ± 0.575 
c-fms -2.1 ± 0.52 NTPdase 1 -2.85 ± 0.50 
TRAP -2.3  ± 0.13 NTPdase 3 1.83 ± 0.57 
CICN7 -1.2 ± 0.10 NDPK -1.8 ± 0.27 
V-ATPase 1.1 ± 0.29   
Osteoblasts    
Ocn 3.3 ± 0.78*  TNAP 1.94 ±.476 
Opn 6.0 ± 0.14***  NPP1 -1.3 ± 0.48 
On 1.49 ± 0.18 NPP3 -1.13 ± 0.20 
Col1α1 1.67 ± 0.51 NTPdase 1 1.42 ± 0.41 
Runx2 1.28 ± 0.07 NTPdase 3 1.22 ± 0.391 
RANKL 1.28 ± 0.34 NDPK 1.44 ± 0.249 
M-CSF 1.09 ± 0.33   
Opg 4.52 ± 0.13 **   
 
Data obtained from qPCR. Values are means ± SEM (n = 4). Significantly different from 
controls * = p<0.05, ** = p<0.01, ** = p<0.001. 
RANK = receptor activator of nuclear factor ΚB, c-fms = M-CSF receptor, TRAP = tartrate 
resistant acid phosphatase, CICN7 = chloride channel CICN7, NPP1/3 = ecto-nucleotide 
pyrophosphatase/phosphodiesterase 1/3,  NTPdase = ecto-nucleoside triphosphate 
diphosphohydrolase, NDPK = nucleoside diphosphokinase, Ocn = osteocalcin, Opn = 
osteopontin, TNAP = alkaline phosphatase, On = osteonectin, Col1α1= collagen 1 alpha 1, 
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Runx2= runt related transcription factor 2, RANKL = receptor activator of nuclear factor ΚB 
ligand, M-CSF = macrophage colony stimulating factor, Opg = osteoprotegerin 
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